The significance of galectin-9 and T-cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) in patients with chronic lymphocytic leukemia: The role of immune evasion.
Study quantifies immune checkpoint proteins in chronic leukaemia, supporting their use as prognostic markers and combination therapy targets.
Hussein et al. measured galectin-9 and TIM-3 in a prospective CLL patient cohort, demonstrating upregulation correlating with Rai staging and immune suppression markers in Human Immunology. The study provides quantitative clinical data supporting these immune checkpoint proteins as prognostic biomarkers in CLL and potential targets for combination immunotherapy strategies in this disease.
What the study was
- Study design
- Prospective observational study
- Population
- CLL patients and healthy controls
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Hum Immunol
Why it surfaced
Confirmatory prospective study of TIM-3/galectin-9 immune checkpoint pathway in CLL; incrementally relevant to T1 hematologic malignancy topic coverage.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.